<p>She describes the unmet need for patients who no longer respond to the large CDK4/6 class of medicines, and the decades of work she has put into solving the problem of adding CDK2 inhibition into the equation.</p>

She describes the unmet need for patients who no longer respond to the large CDK4/6 class of medicines, and the decades of work she has put into solving the problem of adding CDK2 inhibition into the equation.

Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance

Members of the Biotech CEO Sisterhood regularly interview women leaders in biotech about news, science, management topics and more. Tune in to hear from top leaders in biotech about topics that matter to the industry.

Share Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance

Sign up to save your podcasts

Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance

Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance

More shows like Biotech CEO Sisterhood

Odd Lots

Up First from NPR

The Readout Loud

The Journal.

Business Of Biotech

BioCentury This Week

Biotech Hangout

The Studio at Kendall Square

Off-Target Effects with Matt Gline

BioVenture VoiCes with Chris Garabedian

BiotechTV - News